EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Nusrath Sultana, MD, has joined Surmodics as Vice President, Clinical Affairs, effective February 3, 2020.
“We are fortunate to have someone of Nusrath’s caliber joining the Surmodics team,” said Gary Maharaj, President and Chief Executive Officer of Surmodics. “She brings a wealth of experience and a proven track record of success that make her the ideal person to lead clinical affairs. Nusrath’s leadership will be critical to our clinical strategy, and the design and conduct of effective clinical trials with the highest ethical and safety standards.”
Sultana brings more than 20 years of medical affairs, medtech, and healthcare experience. Prior to joining Surmodics, she served as Senior Director, Global Medical Affairs at Edwards Lifesciences, a global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Sultana was responsible for the development of medical affairs infrastructure and provided leadership, oversight and strategic direction for core medical affairs activities. Prior to her time at Edwards Lifesciences, Sultana held numerous positions—most recently Senior Director, Global Clinical Operations—at St. Jude Medical. She holds an MD from Deccan College of Medical Science in Hyderabad, India, and an MBA in Medical Group Management from the University of St. Thomas in St. Paul, Minnesota.
“I am excited to join the Surmodics team and look forward to helping the company achieve its vision,” said Sultana. “The ongoing clinical initiatives and multiple product platforms have the potential to provide meaningful benefits for patients undergoing peripheral vascular treatment. I am honored to be a part of this journey.”
As Vice President, Clinical Affairs, Sultana will be responsible for executive oversight and overall management of the company’s clinical study programs and clinical trial design and execution. She will be a member of the senior leadership team reporting directly to Maharaj.
About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations regarding the Company’s performance in the near- and long-term, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2019. These reports are available in the Investors section of our website at https://surmodics.gcs-web.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.